Sandoz Group AG | WebDisclosure

Basculer en Français

10964	Companies
240038	Keywords
168782	Articles
129138	Press releases

Home
Companies
Sandoz Group AG

PRESS RELEASE

published on 11/24/2025 at 07:00, 9 months 17 days ago

Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases
Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases. Afqlir® matches reference medicine in efficacy, safety, and pharmacokinetics, reinforcing Sandoz commitment to patient access

Retinal Diseases Sandoz Aflibercept Afqlir European Launch
BRIEF

published on 11/17/2025 at 07:05, 9 months 24 days ago

Sandoz lance le premier biosimilaire de la sclérose en plaques, TYRUKO®, aux États-Unis.

Sclérose En Plaques Biosimilaire Sandoz TYRUKO® Natalizumab
BRIEF

published on 11/17/2025 at 07:05, 9 months 24 days ago

Sandoz Launches First MS Biosimilar TYRUKO® in US

Multiple Sclerosis Biosimilar Sandoz TYRUKO® Natalizumab
PRESS RELEASE

published on 11/17/2025 at 07:00, 9 months 24 days ago

Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar
Sandoz launches TYRUKO® (natalizumab-sztn) in US, the first and only multiple sclerosis biosimilar, offering cost-effective treatment. TYRUKO® approved for all indications of reference medicine Tysabri®

US Market Multiple Sclerosis Biosimilar Sandoz TYRUKO
BRIEF

published on 11/12/2025 at 07:40, 9 months 29 days ago

Sandoz obtient une licence mondiale pour un biosimilaire du cancer du sein

Oncologie Biosimilaire Cancer Du Sein Sandoz Pertuzumab
BRIEF

published on 11/12/2025 at 07:40, 9 months 29 days ago

Sandoz Secures Global License for Breast Cancer Biosimilar

Oncology Biosimilar Breast Cancer Sandoz Pertuzumab
PRESS RELEASE

published on 11/12/2025 at 07:35, 9 months 29 days ago

Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab
Sandoz signs global license agreement with EirGenix Inc. to commercialize biosimilar pertuzumab for HER2-positive breast cancer treatment, reinforcing its position in oncology

Agreement Biosimilar Breast Cancer Sandoz Pertuzumab
BRIEF

published on 11/04/2025 at 22:10, 10 months 6 days ago

Sandoz acquiert Just-Evotec Biologics pour développer ses capacités dans le domaine des biosimilaires.

Acquisition Biosimilaires Toulouse Sandoz Just-Evotec
BRIEF

published on 11/04/2025 at 22:10, 10 months 6 days ago

Sandoz Acquires Just-Evotec Biologics to Expand Biosimilars Capabilities

Acquisition Biosimilars Toulouse Sandoz Just-Evotec
PRESS RELEASE

published on 11/04/2025 at 22:05, 10 months 6 days ago

Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-Evotec Biologics EU SAS in Toulouse
Sandoz strengthens biosimilars capabilities with acquisition of Just-Evotec Biologics EU SAS in Toulouse. Acquisition aims to capture projected biosimilar market opportunity. Transaction includes cash payment and technology license fees

Acquisition Biosimilars Sandoz Just-Evotec Biologics Continuous Manufacturing Technology

Accesswire

Published on 09/11/2026 at 04:00, 8 hours 4 minutes ago

Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 13 hours 39 minutes ago

Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 17:46, 18 hours 18 minutes ago

Groete Access Road Nears Completion
Published on 09/10/2026 at 15:20, 20 hours 44 minutes ago

MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 21 hours 4 minutes ago

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 11:45, 18 minutes ago

Halfords Group PLC: Result of AGM
Published on 09/11/2026 at 11:43, 21 minutes ago

Skyborn reaches Financial Close on the Gennaker offshore wind farm project
Published on 09/11/2026 at 11:35, 28 minutes ago

EQS-Adhoc: Correction of a release from 10/09/2026, 19:35 CET/CEST - United Internet AG: Group subsidiaries 1&1 AG and IONOS Group SE launch transformation programs
Published on 09/11/2026 at 11:30, 34 minutes ago

Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
Published on 09/11/2026 at 10:15, 1 hour 49 minutes ago

TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050

Les Echos

Published on 09/11/2026 at 07:00, 5 hours 4 minutes ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 5 hours 4 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 5 hours 4 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 5 hours 4 minutes ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 16 hours 34 minutes ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE